Journal of Parkinson’s Disease Transitioning to Gold Open Access in 2023

18 October 2022

Amsterdam, October 20, 2022 – The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce that beginning in January 2023, JPD will transition to a Gold Open Access publication. This means that all articles published after that date will be immediately and permanently freely available online for readers to view, download, share, and reuse, and will enable authors to more easily comply with funder and institutional mandates.

“When JPD launched 12 years ago, among our primary goals was and continues to be the widespread dissemination of content to further advancements in Parkinson’s disease (PD) research and benefit patients’ quality of life and outcomes,” explained co-Editors-in-Chief Bas Bloem, MD, PhD, FRCPE, and Lorraine V. Kalia, MD, PhD, FRCPC. “Therefore, we are extremely happy to support the next step in the journal’s evolution: migration to a fully open access publication model.”

With a strong Journal Impact Factor of 5.520 and Cite Score of 6.1, JPD is now recognized as one of the most influential journals in the world devoted exclusively to PD. In recent years the number of open access papers published in JPD has been steadily increasing, so that now approximately half are publicly available. The transition to fully open content will increase the journal’s impact and benefit the entire PD community, including authors, readers, libraries, hospitals, funding agencies – and ultimately patients.

JPD offers a rigorous peer-review process and operates with rapid manuscript processing times. The average time from submission to first decision is 18 days (the median average is 13 days). Accepted papers submitted from November 1, 2022, will be published Open Access under a Creative Commons license, and authors and will retain copyright to their published work.

The associated open access fee has been set to be extremely competitive compared to those set by other journals in the field. The fee will not apply to certain publication types, like invited articles, editorials, and commentaries. Fees may be waived under certain circumstances, particularly from low-income countries as defined by HINARI, upon application from the authors.

“The migration of one of our flagship journals to Gold Open Access is very exciting for us at IOS Press,” noted Publisher Rasjel van der Holst. “We are supportive of exploring new options facilitated by an evolving open access publishing landscape and meeting the growing expectations related to open access. JPD joins our expanding portfolio of open content journals and books.”

Instructions for authors can be found here.


For additional information, contact Rasjel van der Holst, IOS Press (

About the Journal of Parkinson's Disease
The Journal of Parkinson's Disease (JPD) is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of Parkinson’s disease. The journal is international and multidisciplinary and aims to promote progress in the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pharmacology, psychology, diagnosis, and treatment of Parkinson’s disease. It publishes research reports, reviews, short communications, and letters-to-the-editor and offers very rapid publication and an affordable open access option. JPD has a 2020 Journal Impact Factor of 5.568 according to Journal Citation Reports (Clarivate, 2021) and is published by IOS Press.

About IOS Press
IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in biomedical and life sciences (including neurosciences, medical informatics, cancer research, rehabilitation) and physical sciences (including computer sciences, artificial intelligence, engineering). In addition, we offer specialized services that support scientific advancement.